Holen Sie sich die Stockscreener-App
5.00
4.50%
0.11
Schlusskurs vom Vortag:
$4.89
Offen:
$5.06
24-Stunden-Volumen:
31,962
Relative Volume:
0.58
Marktkapitalisierung:
$144.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.24%
1M Leistung:
-8.26%
6M Leistung:
+65.91%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.925
$5.39
1-Wochen-Bereich:
$4.70
$5.59
52-Wochen-Spanne:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Firmenname
Insight Molecular Diagnostics Inc
Sektor
Branche
Telefon
949-409-7600
Adresse
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
5.05 | 140.27M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
469.34 | 176.79B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
186.44 | 131.71B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
569.80 | 45.48B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.47 | 31.55B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
284.30 | 27.79B | 3.17B | 642.63M | 516.49M | 10.77 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Eingeleitet | Lake Street | Buy |
| 2022-05-24 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-03-17 | Fortgesetzt | Needham | Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Eingeleitet | BTIG Research | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Bestätigt | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Eingeleitet | Needham | Buy |
| 2019-02-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-29 | Hochstufung | Janney | Neutral → Buy |
| 2018-12-19 | Fortgesetzt | Lake Street | Buy |
Alle ansehen
Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten
Insight Molecular Diagnostics Inc Highlights New Peer-Reviewed Study Demonstrating GraftAssure Assay Technology Superiority - marketscreener.com
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score - GlobeNewswire
Insight Molecular Diagnostics Nears FDA Submission for Kidney Transplant Rejection Test Kit - Clinical Lab Products
Insight Molecular Diagnostics Nears FDA Submission with GraftAssureDx Milestones - Zenopa
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission - Bitget
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Insight Molecular Diagnostics completes key milestones advancing Graftassuredx toward FDA submission - marketscreener.com
Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission - TradingView
Kidney transplant test GraftAssureDx nears FDA submission in $2B market - Stock Titan
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx Catalyst - Yahoo Finance
Insight Molecular Diagnostics enters agreement with Quest DiagnosticsSEC filing - marketscreener.com
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement - TipRanks
In Insight Molecular Diagnostics Inc. Enters into A Specimen Collection Agreement with Quest Diagnostics Incorporated - marketscreener.com
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Insight Molecular Diagnostics Inc. has reached a service agreement with Quest Diagnostics. - Bitget
Insight Molecular Diagnostics (IMDX) Price Target Increased by 19.05% to 8.50 - Nasdaq
Kidney Transplant Rejection Market Overview: Major Segments, Strategic Developments, and Leading Companies - openPR.com
IMDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Molecular Biology Analyzers Market Set to Boom by 2033: - openPR.com
Insight Molecular (IMDX) Sees Analyst Price Target Raised to $12 - GuruFocus
Of Note: Nashville Zoo adds to board - Nashville Post
Insider Stock Purchases: February 13, 2026 - Quiver Quantitative
Insight Molecular Diagnostics Raises Capital to Advance Transplant R&D - TipRanks
Insight Molecular Diagnostics Signs Multiple Material Agreements - TradingView
From $54B to $85B: A Promising Decade for North America IVD - GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Imdx announces $26.0 million registered direct offering - marketscreener.com
Insight Molecular Diagnostics (IMDX) Secures $26M in Direct Stoc - GuruFocus
Insight Molecular Diagnostics prices $26M registered direct offering; shares down - MSN
Insight Molecular Diagnostics Provides Updated Investor Presentation Materials - TipRanks
iMDx Announces $26.0 Million Registered Direct Offering - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Boston Scientific (BSX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Steris (STE) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Artivion (AORT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), NewAmsterdam Pharma Company (NAMS) and Resmed (RMD) - The Globe and Mail
Gastric Cancer Diagnostic Procedure Market to Grow at a CAGR of 6.53% - industrytoday.co.uk
Urinary Tract Infection Testing Market | Global Market Analysis Report2036 - Future Market Insights
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$8.13m - simplywall.st
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Dexcom (DXCM) - The Globe and Mail
IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring - marketscreener.com
Insight ‘congratulated’ STAR working group on organ health testing paper - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring - marketscreener.com
Transplant leaders urge decentralized organ rejection tests at hospitals - Stock Titan
iMDx Announces 'JPM Week” and 'BTIG Snowbird” Conference Participation - The Manila Times
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch - Sahm
Is Insight Molecular Diagnostics Inc. (7OC0) stock considered safe haven2026 world cup usa national team quarterfinals midfield engines low block defense group prediction preview - Улправда
Needham reiterates Buy rating on Insight Molecular stock, cites progress on GraftAssureDx - Investing.com Nigeria
Finanzdaten der Insight Molecular Diagnostics Inc-Aktie (IMDX)
Es liegen keine Finanzdaten für Insight Molecular Diagnostics Inc (IMDX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.77%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):